

ENROLLED

CS/HB 967

2023 Legislature

1
 2 An act relating to Medicaid coverage of continuous
 3 glucose monitors; creating s. 409.9063, F.S.; defining
 4 the term "continuous glucose monitor"; requiring the
 5 Agency for Health Care Administration, subject to the
 6 availability of funds and certain limitations and
 7 directions, to provide coverage for continuous glucose
 8 monitors for certain Medicaid recipients; providing
 9 construction; providing requirements for Medicaid
 10 recipients to continue receiving coverage for their
 11 continuous glucose monitors; requiring the agency to
 12 seek federal approval for implementation of the act,
 13 if needed; requiring the agency to include the rate
 14 impact of the act in certain rates that become
 15 effective on a specified date; providing an effective
 16 date.

17
 18 Be It Enacted by the Legislature of the State of Florida:

19
 20 Section 1. Section 409.9063, Florida Statutes, is created
 21 to read:

22 409.9063 Coverage of continuous glucose monitors for
 23 Medicaid recipients.—

24 (1) As used in this section, the term "continuous glucose
 25 monitor" means an instrument or a device designed for the

ENROLLED

CS/HB 967

2023 Legislature

26 purpose of aiding in the treatment of diabetes by measuring
 27 glucose levels on demand or at set intervals through a small,
 28 electronic sensor that slightly penetrates a person's skin when
 29 applied and that is designed to remain in place and active for
 30 at least 7 days.

31 (2) Subject to the availability of funds and subject to
 32 any limitations or directions provided in the General
 33 Appropriations Act, the agency must provide coverage for a
 34 continuous glucose monitor under the Medicaid pharmacy benefit
 35 for the treatment of a Medicaid recipient if:

36 (a) The recipient has been diagnosed by his or her primary
 37 care physician, or another licensed health care practitioner
 38 authorized to make such diagnosis, with Type 1 diabetes, Type 2
 39 diabetes, gestational diabetes, or any other type of diabetes
 40 that may be treated with insulin; and

41 (b) A health care practitioner with the applicable
 42 prescribing authority has prescribed insulin to treat the
 43 recipient's diabetes and a continuous glucose monitor to assist
 44 the recipient and practitioner in managing the recipient's
 45 diabetes.

46 (3) Coverage under this section includes the cost of any
 47 necessary repairs or replacement parts for the continuous
 48 glucose monitor.

49 (4) To qualify for continued coverage under this section,
 50 the Medicaid recipient must participate in follow-up care with

ENROLLED

CS/HB 967

2023 Legislature

51 his or her treating health care practitioner, in person or
52 through telehealth, at least once every 6 months during the
53 first 18 months after the first prescription of the continuous
54 glucose monitor for the recipient has been issued under this
55 section, to assess the efficacy of using the monitor for
56 treatment of his or her diabetes. After the first 18 months,
57 such follow-up care must occur at least once every 12 months.

58 (5) The agency shall seek federal approval, if needed, for
59 the implementation of this section.

60 Section 2. The Agency for Health Care Administration shall
61 include the rate impact of this act in the Medicaid managed
62 medical assistance program and long-term care managed care
63 program rates, as applicable, that take effect on October 1,
64 2023.

65 Section 3. This act shall take effect October 1, 2023.